Targeted Regulatory Writing Techniques: Clinical Documents for Drugs and Biologics
- ISBN-10
- 3764383623
- ISBN-13
- 9783764383626
- Category
- Medical
- Pages
- 238
- Language
- English
- Published
- 2009-01-05
- Publisher
- Springer Science & Business Media
- Authors
- Linda Fossati Wood, MaryAnn Foote
Description
This book describes the authors’ standard or ‘best’ practices used in writing regul- ed clinical documents for the drug and biologics industry. The fundamental premise of this book is that the end (documents submitted to a health authority) is dep- dent on the beginning (the planning and strategy that go into organizing written documentation). Each regulatory document inherently exists within a constellation of related documents. This book attempts to show the relationships between and among these documents and suggests strategies for organizing and writing these documents to maximize ef?ciency while developing clear and concise text. At all times, and irrespective of applicable laws and guidelines, good communication skills and a sense of balance are essential to adequately, accurately, and clearly describe a product’s characteristics. At no time should the reader perceive these suggestions to be the only viable solution to writing regulatory documents nor should the reader expect that these suggestions guarantee product success. The audience for this book is the novice medical writer, or those who would like to explore or enhance regulatory-writing skills. We assume the reader will have a basic understanding of written communication, but little experience in applying this skill to the task of regulatory writing. Extensive knowledge of science, clinical me- cine, mathematics, or regulatory affairs law is not required to use the best practices described in this book.
Get the book
Other editions
-
- 2008-11-18
- 235 pages
- Paperback
- Springer Science & Business Media
Similar books
-
Publishing and Presenting Clinical Research
By Warren S. BrownerThis edition contains the latest: • Guidance on getting work accepted in medical journals and at scientific meetings • Examples of the do’s and don’ts of data presentation • Explanations of confusing statistical terminology • ...
-
Clinical Trials: Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines
By Tom BrodyGuidance for industry. Good pharmacovigilance practices and pharmacoepidemiologic assessment; March 2005 (20 pp.). 1Kotterman MA, Schaffer DV. Engineering adeno-associated viruses for clinical gene CLINICAL TRIALS 568 25.
-
Regulatory Writing: an Overview, Second Edition
By Gloria Hall, Lisa DeToraRegulatory Writing: an Overview, Second Edition
-
Information Resources in Toxicology: Volume 1: Background, Resources, and Tools
By Steve Gilbert, Asish Mohapatra, Sol BobstIn: Goldfrank, L.R., et al., (Eds.), Goldfrank's Toxicologic Emergencies, eighth ed. ... The second edition broadened coverage from chemotherapy to a wide variety of biochemical systems, and thus to a range of scientific disciplines in ...
-
Clinical Research and the Law
By Patricia M. TereskerzDr. Wilson will not serve as a sponsor of an FDA-regulated clinical trial for a five year period starting today. He has not been involved with human research participants since January 2000. 2. Dr. Wilson must meet imposed ...
-
Modern CNS Drug Discovery: Reinventing the Treatment of Psychiatric and Neurological Disorders
By Rudy SchreiberThe book’s final chapter addresses the registration for newly developed drugs. Written by experts from academia and industry, the book covers important basics and best practices, as well as recent developments in drug discovery.
-
Regulatory Writing: An Overview
By Steve Carr, Michelle Carey, Jocelyn Jennings"This book concentrates on the writerly aspects of regulatory documentation and is intented to help the novice and to provide a refresher for more seasoned professionals.
-
FDA Regulatory Affairs: Third Edition
By Douglas J. Pisano, David MantusThe Third Edition of this highly successful publication: Examines the harmonization of the US Federal Food, Drug, and Cosmetic Act with international regulations on human drug, biologics and device development, research, manufacturing, and ...
-
New Drug Development: A Regulatory Overview
By Mark P. MathieuNew Drug Development: A Regulatory Overview
-
Regulatory Affairs in the Pharmaceutical Industry
By Javed Ali, Sanjula BabootaRegulatory Affairs in the Pharmaceutical Industry is a comprehensive reference that compiles all the information available pertaining to regulatory procedures currently followed by the pharmaceutical industry.